|
Press Release
Dr. Richard Nichol Joins Skila’s Board of Directors
Morris Plains, NJ – August 23, 2011 - Skila, a leading provider of fully managed Software-as-a-Service (SaaS) product launch management and key opinion leader (KOL) management solutions to pharmaceutical and medical device companies, announced today that Dr. Richard Nichol, Ph.D. has joined the company’s Board of Directors, effective immediately.
Dr. Nichol brings to Skila more than 40 years of management, global market strategy and corporate governance experience in the pharmaceutical and biotechnology industry. Dr. Nichol has served on six private and public corporate boards, was named a finalist for Entrepreneur of the Year, Orange County, CA in 1990, and was Chairman of the Chief Executive Roundtable, University of California, Irvine, from 1996 to 1997.
“We are excited to have Dr. Nichol join our Board of Directors. He is an excellent addition and I expect he will make an immediate impact on our vision and business initiatives. I am personally looking forward to working closely with him,” said Drew McCartney, Chief Executive Officer of Skila.
Harold Blue, Managing Partner of BelHealth Investment Partners L.P., and Chairman of the Board of Skila, said “We are excited to have Dr. Nichol join our Board of Directors. He brings just what we need - deep pharmaceutical experience and background helping growing companies execute on their business plans. His efforts will immediately accelerate our strategic partnering efforts as well as benefit our existing relationships. As Skila’s lead outside director he will be an important contributor to our Board as we focus on growing Skila.”
“In today’s economic climate most companies are looking for quick ROIs when they evaluate technology and Skila clearly delivers those results to the life sciences industry. In my role on the Board of Directors, I look forward to helping the team as Skila continues to grow,” said Dr. Nichol.
About BelHealth Investment Partners
BelHealth Investment Partners L.P. (“BelHealth”) is a private equity buyout fund focused exclusively on the small-cap healthcare industry. BelHealth acquires majority positions in healthcare companies that the BelHealth Team believes are undervalued or undermanaged and would benefit from the vast entrepreneurial and operating experience that BelHealth can deliver. Applying an active, hands-on approach to governance, BelHealth utilizes its experience to drive revenue and profit growth and achieve superior returns for its investors. For more information about BelHealth, please visit: www.BelHealth.com.
|
About Skila
Skila, a BelHealth investment company, is a global technology and services company specializing in fully managed "Solution" as-a-Service (SaaS) product launch lifecycle management and engagement / relationship management solutions for the healthcare industry. Skila’s solutions address the broad needs of global marketing, medical, market access, executive and alliance management teams that include a unique methodology, robust technology and key continuous services for effectively managing global product launches, key opinion leader relationships, market access / managed care, business performance, competitive intelligence, and key partnerships and alliances.
Having developed strong relationships with a broad number of global pharmaceutical companies, Skila’s solutions have been deployed in 61 countries, supporting numerous global brands and more than 10 million user interactions. Skila’s long-standing commitment and understanding of customers’ needs has resulted in the exponential growth and adoption of our methodology, technology and continuous services as the business platform of choice for our clients.
BelHealth is a private healthcare investment fund. For more info, visit www.belhealth.com.
To receive more information:
Do You Skila?
|
